Journal profile · Oncology
Clinical Cancer Research
ISSN 1078-0432 · eISSN 1557-3265 · American Association for Cancer Research Inc. · UNITED STATES · Semimonthly · Founded 1995
Clinical Cancer Research: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 10.78; hybrid open access; median 132 days to acceptance (127 articles, last 24 months); community-reported acceptance: about 30%; 2,761 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Cancer Research is published by American Association for Cancer Research Inc. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies and Cancer Genomics and Diagnostics, together about 23.3% of its articles. Its main subfields are Oncology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.2%
- Advanced Breast Cancer TherapiesMedicine7.7%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7.3%
- HER2/EGFR in Cancer ResearchMedicine6.3%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.5%
- Lung Cancer Treatments and MutationsMedicine5.2%
- Cancer Cells and MetastasisMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 10.78LetPub ·
- CiteScore 2026-06
- 17.3LetPub ·
- SJR 2026-06
- 4.75LetPub ·
- SNIP 2026-06
- 2.1LetPub ·
- h-index
- 292LetPub ·
- h-index
- 423OpenAlex ·
- i10-index
- 15,414OpenAlex ·
- 2-year mean citedness
- 2.15OpenAlex ·
- Self-citation rate
- 1.8%LetPub ·
- Share of gold OA articles
- 36.57%LetPub ·
Volume
- Articles per year
- 457LetPub ·
Articles by year OpenAlex count · 27,748 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 2,591 | 244 | 595 |
| 2025 | 2,761 | 368 | 4,040 |
| 2024 | 874 | 404 | 8,727 |
| 2023 | 668 | 422 | 14,916 |
| 2022 | 748 | 506 | 23,726 |
| 2021 | 1,059 | 550 | 37,555 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
132 daysMedian, submission to acceptance · P25–P75 108 days – 171 days
- Acceptance to online
- median 6 days (48 articles)
- Submission to online
- median 152 days
- Sample
- 127 articles with submission and acceptance dates (1,123 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.1 monthsLetPub ·
- Average acceptance (community reports)
- 30%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Association for Cancer Research Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Semimonthly
- Founded
- 1995
- ISSN
- 1078-0432
- Electronic ISSN
- 1557-3265
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Clinical Cancer Research
What CAS zone is Clinical Cancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Cancer Research is in Zone 1 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Cancer Research?
The latest impact factor listed by LetPub is 10.78; CiteScore 17.3, h-index 423.
How long does peer review take at Clinical Cancer Research?
Based on the dates recorded on 127 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 132 days (interquartile range 108–171 days); authors report an average review time of about 2.1 months; the community-reported acceptance is “about 30%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Clinical Cancer Research?
According to LetPub and DOAJ records, Clinical Cancer Research is indexed in SCIE and Scopus.
Is Clinical Cancer Research open access, and what is the APC?
Clinical Cancer Research is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .